New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
10:02 EDTEZPW, AMX, WFC, RKT, MTRN, IGT, DVA, AUO, SAVE, RH, ITRI, GRT, AMOV, SHPG, MNST, LFLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AU Optronics (AUO) downgraded to Sell from Neutral at UBS... America Movil downgraded to Underweight from Equal Weight at Morgan Stanley... DaVita (DVA) downgraded to Market Perform from Outperform at Raymond James... EZCORP (EZPW) downgraded to Neutral from Buy at Sidoti... Glimcher Realty Trust (GRT) downgraded to Market Perform at Raymond James... International Game (IGT) downgraded to Hold from Buy at Stifel... Itron (ITRI) downgraded at BofA/Merrill... LATAM Airlines (LFL) downgraded to Neutral from Buy at BofA/Merrill... Materion (MTRN) downgraded to Hold from Buy at KeyBanc... Monster Beverage (MNST) downgraded at Morgan Stanley... Restoration Hardware (RH) downgraded at BB&T... RockTenn (RKT) downgraded to Neutral from Outperform at Macquarie... Shire (SHPG) downgraded to Market Perform from Outperform at Leerink... Spirit Airlines (SAVE) downgraded to Equal-Weight from Overweight at Evercore... Wells Fargo (WFC) downgraded to Hold from Buy at Rafferty Capital.
News For AUO;AMX;AMOV;DVA;EZPW;GRT;IGT;LFL;ITRI;MTRN;MNST;RH;RKT;SHPG;SAVE;WFC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 10, 2015
06:31 EDTWFCGeneral Electric to sell most of GE Capital assets for approximately $26.5B
Subscribe for More Information
April 9, 2015
16:17 EDTWFCOn The Fly: Closing Wrap
Subscribe for More Information
13:38 EDTWFCGE close to selling real estate holdings, WSJ reports
General Electric (GE) is close to selling its real estate holdings to Blackstone (BX) and Wells Fargo (WFC), Wall Street Journal reports, citing people familiar with the matter. The portfolio has $30B in holdings, the Journal adds. Shares of GE moved up 25c to $25.26 following the report. Reference Link
13:27 EDTSHPGShire announces FDA Priority Review designation for lifitegrast
Subscribe for More Information
10:48 EDTSHPGDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
12:29 EDTDVADaVita sees roughly $50M impact to FY16 operating income from Medicare rates
Subscribe for More Information
11:29 EDTMNSTOptions with increasing implied volatility
Subscribe for More Information
06:10 EDTRKTRockTenn pullback brings attractive entry point, says Citigroup
Citigroup sees an attractive entry point into RockTenn with the recent pullback taking away most of the stock's year-to-date gains. Citi expects RockTenn's merger with MeadWestvaco (MWV) to bring increased earnings growth and reiterates a Buy rating on the stock with a $77 price target.
April 7, 2015
12:36 EDTMNSTOptions with increasing implied volatility
Subscribe for More Information
11:04 EDTIGTInternational Game, GTECH complete combination
Subscribe for More Information
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
09:48 EDTIGTInternational Game rallies to fresh 52-week high, levels to watch
Subscribe for More Information
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
08:04 EDTAMOV, AMXAsurion announces new partnership with America Movil
Subscribe for More Information
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
06:02 EDTDVAFinal Medicare Advantage rates better for DaVita, says Wells Fargo
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
April 6, 2015
12:47 EDTWFCWells Fargo April volatility increases into Q1 and outlook
Wells Fargo April call option implied volatility is at 22, May is at 17, June is at 15; compared to its 26-week average of 17 according to Track Data, suggesting large near term price movement in the expected release of Q1 results on April 14.
09:09 EDTSHPGShire says will defend patents 'vigorously' after Hayman petitions
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use